A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control

Peter W. Choo, Cynthia S. Rand, Thomas Inui, Mei Ling Ting Lee, Claire Canning, Richard Platt

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives - To evaluate if antihypertensive regimens that conform to present FDA guidelines by maintaining ≥50% of their peak effect at the end of the dosing interval protect patients during sporadic lapses in adherence. Methods - 169 patients on monotherapy for high blood pressure underwent electronic adherence monitoring for 3 months. Blood pressures were measured during non-study office visits and were retrieved from automated medical records. Questionnaires were used to obtain other covariate information. The ratio of the dosing interval to the half-life of drug activity (I′) was used to capture conformity with FDA guidelines. Data analysis focused on the interaction between I′ and the impact on blood pressure of delayed dosing. Results - The average (± standard deviation) blood pressure during the study was 139.0(±12.0)/85.0(±6.9) mm Hg. Lisinopril followed by sustained-release verapamil, atenolol, and hydrochlorothiazide were the most frequently prescribed agents. The majority of regimens (99%) conformed to FDA dosing guidelines. Of the patients 23% missed a dose before their blood pressure check. Non-adherence, however, did not have a direct impact on blood pressure, and no interaction with I′ of was detected. Conclusions - Among patients with relatively mild hypertension on single-drug therapy, regimens that conform to current FDA dosing guidelines may prevent losses of blood pressure control during episodic lapses of adherence. These findings should be replicated in other patient populations with standardized blood pressure measurement to confirm their validity.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalPharmacoepidemiology and Drug Safety
Volume9
Issue number7
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Antihypertensive Agents
Blood Pressure
Guidelines
Hypertension
Lisinopril
Office Visits
Hydrochlorothiazide
Atenolol
Verapamil
Medical Records
Half-Life
Drug Therapy
Pharmaceutical Preparations
Population

Keywords

  • Adherence
  • Compliance
  • Hypertension
  • Pharmacodynamics
  • Statistical interaction

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control. / Choo, Peter W.; Rand, Cynthia S.; Inui, Thomas; Lee, Mei Ling Ting; Canning, Claire; Platt, Richard.

In: Pharmacoepidemiology and Drug Safety, Vol. 9, No. 7, 2000, p. 557-563.

Research output: Contribution to journalArticle

Choo, Peter W. ; Rand, Cynthia S. ; Inui, Thomas ; Lee, Mei Ling Ting ; Canning, Claire ; Platt, Richard. / A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control. In: Pharmacoepidemiology and Drug Safety. 2000 ; Vol. 9, No. 7. pp. 557-563.
@article{fc8b03dbaa5d4183b7be46edbf41ca32,
title = "A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control",
abstract = "Objectives - To evaluate if antihypertensive regimens that conform to present FDA guidelines by maintaining ≥50{\%} of their peak effect at the end of the dosing interval protect patients during sporadic lapses in adherence. Methods - 169 patients on monotherapy for high blood pressure underwent electronic adherence monitoring for 3 months. Blood pressures were measured during non-study office visits and were retrieved from automated medical records. Questionnaires were used to obtain other covariate information. The ratio of the dosing interval to the half-life of drug activity (I′) was used to capture conformity with FDA guidelines. Data analysis focused on the interaction between I′ and the impact on blood pressure of delayed dosing. Results - The average (± standard deviation) blood pressure during the study was 139.0(±12.0)/85.0(±6.9) mm Hg. Lisinopril followed by sustained-release verapamil, atenolol, and hydrochlorothiazide were the most frequently prescribed agents. The majority of regimens (99{\%}) conformed to FDA dosing guidelines. Of the patients 23{\%} missed a dose before their blood pressure check. Non-adherence, however, did not have a direct impact on blood pressure, and no interaction with I′ of was detected. Conclusions - Among patients with relatively mild hypertension on single-drug therapy, regimens that conform to current FDA dosing guidelines may prevent losses of blood pressure control during episodic lapses of adherence. These findings should be replicated in other patient populations with standardized blood pressure measurement to confirm their validity.",
keywords = "Adherence, Compliance, Hypertension, Pharmacodynamics, Statistical interaction",
author = "Choo, {Peter W.} and Rand, {Cynthia S.} and Thomas Inui and Lee, {Mei Ling Ting} and Claire Canning and Richard Platt",
year = "2000",
doi = "10.1002/pds.539",
language = "English (US)",
volume = "9",
pages = "557--563",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control

AU - Choo, Peter W.

AU - Rand, Cynthia S.

AU - Inui, Thomas

AU - Lee, Mei Ling Ting

AU - Canning, Claire

AU - Platt, Richard

PY - 2000

Y1 - 2000

N2 - Objectives - To evaluate if antihypertensive regimens that conform to present FDA guidelines by maintaining ≥50% of their peak effect at the end of the dosing interval protect patients during sporadic lapses in adherence. Methods - 169 patients on monotherapy for high blood pressure underwent electronic adherence monitoring for 3 months. Blood pressures were measured during non-study office visits and were retrieved from automated medical records. Questionnaires were used to obtain other covariate information. The ratio of the dosing interval to the half-life of drug activity (I′) was used to capture conformity with FDA guidelines. Data analysis focused on the interaction between I′ and the impact on blood pressure of delayed dosing. Results - The average (± standard deviation) blood pressure during the study was 139.0(±12.0)/85.0(±6.9) mm Hg. Lisinopril followed by sustained-release verapamil, atenolol, and hydrochlorothiazide were the most frequently prescribed agents. The majority of regimens (99%) conformed to FDA dosing guidelines. Of the patients 23% missed a dose before their blood pressure check. Non-adherence, however, did not have a direct impact on blood pressure, and no interaction with I′ of was detected. Conclusions - Among patients with relatively mild hypertension on single-drug therapy, regimens that conform to current FDA dosing guidelines may prevent losses of blood pressure control during episodic lapses of adherence. These findings should be replicated in other patient populations with standardized blood pressure measurement to confirm their validity.

AB - Objectives - To evaluate if antihypertensive regimens that conform to present FDA guidelines by maintaining ≥50% of their peak effect at the end of the dosing interval protect patients during sporadic lapses in adherence. Methods - 169 patients on monotherapy for high blood pressure underwent electronic adherence monitoring for 3 months. Blood pressures were measured during non-study office visits and were retrieved from automated medical records. Questionnaires were used to obtain other covariate information. The ratio of the dosing interval to the half-life of drug activity (I′) was used to capture conformity with FDA guidelines. Data analysis focused on the interaction between I′ and the impact on blood pressure of delayed dosing. Results - The average (± standard deviation) blood pressure during the study was 139.0(±12.0)/85.0(±6.9) mm Hg. Lisinopril followed by sustained-release verapamil, atenolol, and hydrochlorothiazide were the most frequently prescribed agents. The majority of regimens (99%) conformed to FDA dosing guidelines. Of the patients 23% missed a dose before their blood pressure check. Non-adherence, however, did not have a direct impact on blood pressure, and no interaction with I′ of was detected. Conclusions - Among patients with relatively mild hypertension on single-drug therapy, regimens that conform to current FDA dosing guidelines may prevent losses of blood pressure control during episodic lapses of adherence. These findings should be replicated in other patient populations with standardized blood pressure measurement to confirm their validity.

KW - Adherence

KW - Compliance

KW - Hypertension

KW - Pharmacodynamics

KW - Statistical interaction

UR - http://www.scopus.com/inward/record.url?scp=0034456327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034456327&partnerID=8YFLogxK

U2 - 10.1002/pds.539

DO - 10.1002/pds.539

M3 - Article

C2 - 11338913

AN - SCOPUS:0034456327

VL - 9

SP - 557

EP - 563

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 7

ER -